Navigation Links
Biotech collaboration established to commercialize research reagents
Date:10/18/2010

The Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, has entered a collaboration with New Jersey-based medical technology company BD to evaluate and potentially develop for research and diagnostic use some of the institute's reagents.

The institute has a portfolio of more than 100 monoclonal antibodies produced through its in-house antibody facility for research into cancer, chronic inflammatory diseases and infectious diseases.

The collaboration, with BD's Biosciences segment, will build on programs at the institute that are focused on identifying novel targets for therapeutic monoclonal antibody and drug development.

Under the terms of the agreement, BD will make upfront and annual payments to the institute as well as royalty payments on sales of any licensed antibodies in return for a first option to evaluate and commercialise antibodies from the institute. The financial terms of the collaboration are confidential.

The institute's business development manager Dr James Dromey said antibodies were an important tool in the lab as well as the clinic, where they are used as diagnostic tools and biomarkers.

"This is a wonderful opportunity for the institute to share its internal resources and scientific expertise with the wider scientific community and to improve the possibility of the institute's technology being commercialised and having a positive impact on research and diagnostic markets," Dr Dromey said.

"The institute's strategic research interests align well with those of BD, particularly in key areas such as cancer, programmed cell death (apoptosis), stem cells and immunology. This is the first commercial contract that we have established for wider utilisation of institute reagents, and we hope it will be the first step in a broader collaboration with BD."

The institute has a track record for producing commercially available and successful products, including the LIF protein, which is essential for the maintenance of embryonic stem cells, and the pGex fusion protein vector.

Antibody production and related services form one of the most important technology platforms that underpin the institute's successful science and commercialisation activities. The institute's 'discovery pipeline' is fed by more than 250 research projects, many involving development of new antibodies through its in-house antibody facility.


'/>"/>

Contact: Penny Fannin
fannin@wehi.edu.au
61-393-452-345
Walter and Eliza Hall Institute
Source:Eurekalert  

Related biology news :

1. Developments in nanobiotechnology at UCSB point to medical applications
2. New biotech company grows from MCG diabetes and genomic research
3. $31 million biotech center to benefit crops, food, energy
4. Success with cisgenics in forestry offers new tools for biotechnology
5. Cutting-edge vaccine research to be showcased at AAPS National Biotechnology Conference
6. Biotherapeutic Innovations on Display at AAPS National Biotechnology Conference
7. AAPS immunogenicity training course to be offered prior to national biotechnology conference
8. UT Southwesterns BioCenter driving biotech, medical innovation in North Texas
9. NYU School of Medicine presents biomedical researchers Dart/NYU Biotechnology Achievement Awards
10. GenWay Biotech extends the You Test You program overseas
11. New biotech advance to add heart healthy omega-3s to US diet
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biotech collaboration established to commercialize research reagents
(Date:11/17/2016)... LONDON , Nov. 17, 2016 Global Market ... and Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market ... Geographical analysis for Private Biobanks shows the highest Compounded Annual ... Asia-Pacific region during the analysis period 2014-2020. ... a CAGR of 9.95% followed by Europe ...
(Date:11/14/2016)... Nov. 14, 2016  xG Technology, Inc. ("xG" or ... critical wireless communications for use in challenging operating environments, ... 30, 2016. Management will hold a conference call to ... p.m. Eastern Time (details below). Key Recent ... $16 million binding agreement to acquire Vislink Communication Systems. ...
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... December 02, 2016 , ... ... biotechnology companies dedicated to collaboratively developing improved chemistry, manufacturing and control technologies ... portable online UHPLC, with robust, probe-based sampling. , Online liquid chromatography ...
(Date:12/2/2016)... 1, 2016   SurePure, Inc. (OTCQB: SURP) ... the Company has concluded an agreement with Tamarack Biotics ... 90-day period to acquire units of the Company,s patented ... 3.7 million.  Concurrently with the option, ... which Tamarack will seek regulatory approvals in ...
(Date:12/2/2016)... world leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton ... HIV Self Test to 350 pharmacy representatives in Nairobi and ...
(Date:11/30/2016)... , Nov. 30, 2016  GenomOncology today announced the appointment ... of Medical Affairs.  Dr. Coleman will oversee ... company,s proprietary knowledge-enabled platform. The GenomOncology software suite empowers molecular ... sequencing data and clinical decision support, from quality control through ... , , ...
Breaking Biology Technology: